{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037162","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.463427+00:00","generated_at":"2026-06-12T13:34:55.124631+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"REGENXBIO Q2 net loss $72.1M ($1.66/sh); revenue $20M; RGX-121 enrollment complete","bullets":["Net loss widened to $72.1M vs $68.2M YoY; diluted EPS -$1.66.","Revenue fell to $20.0M from $32.6M; Zolgensma royalty revenue down to $19.0M.","Cash, equivalents and marketable securities $415.4M; runway into 2025.","Completed enrollment (10 patients) in Phase III CAMPSIITE trial for RGX-121; BLA filing planned 2024.","ABBV-RGX-314 suprachoroidal dose level 3 with short-course steroids showed zero intraocular inflammation (N=39)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037162","json":"https://secwatch.observer/filing/0000950170-23-037162.json","markdown":"https://secwatch.observer/filing/0000950170-23-037162.md","text":"https://secwatch.observer/filing/0000950170-23-037162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023037162/0000950170-23-037162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023037162/rgnx-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T13:34:55.124631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}